332P - Ribociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
| Autor: | De Laurentiis, M., Ring, A., Campone, M., Bachelot, T., Jacot, W., Marchetti, P., Timcheva, C., De Valk, B., Gombos, A., Menon-Singh, L., Wu, J., Zhou, K., Neven, P. |
|---|---|
| Zdroj: | In Annals of Oncology October 2019 30 Supplement 5:v117-v118 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|